Smartwatch ECG tested for heart risk in childhood cancer survivors
NCT ID NCT05617391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a smartwatch ECG can predict heart muscle disease (cardiomyopathy) in adult survivors of childhood cancer as well as a standard clinic ECG does. About 1,300 survivors will have both a standard 12-lead ECG and a 30-second Apple Smartwatch ECG. The goal is to see if the two match and to build a new model using only the smartwatch ECG to predict heart risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY, PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict growth problems in childhood cancer survivors?
- Exercise as medicine: a new weapon in the fight against childhood cancer?
- Rebooting immunity: can vaccines shield childhood cancer survivors from preventable diseases?
- Can a peer coach help young people take control of their chronic illness?
- Decades after childhood cancer: what Survivors' health reveals
- Could light therapy ease nerve pain from childhood cancer treatment?